PAM
RNTX

Panagora Asset Management’s Rein Therapeutics RNTX Stock Holding History

Panagora Asset Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-175
Closed -$3K – 2654
2019
Q2 		$3K Sell
175
-1,204
-87% -$31.6K ﹤0.01% 2515
2019
Q1 		$54K Buy
1,379
+809
+142% +$25.2K ﹤0.01% 2026
2018
Q4 		$10K Sell
570
-10
-2% -$402 ﹤0.01% 2325
2018
Q3 		$32K Buy
+580
New +$39K ﹤0.01% 2129

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Panagora Asset Management's RNTX Position: Q3 2019 in Review

Panagora Asset Management sold out of Rein Therapeutics (RNTX) in Q3 2019, closing a stake of 175 shares — an estimated $3K sold.

Panagora Asset Management first reported a position in RNTX in Q3 2018 and held it in 4 quarters. The position peaked at $54K in Q1 2019. 22 funds tracked by Wall St. Rank hold RNTX as of Q3 2019.

  • Panagora Asset Management reported no remaining Rein Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Panagora Asset Management sold 175 Rein Therapeutics shares in Q3 2019, an estimated $3K.
  • Panagora Asset Management first reported a position in Rein Therapeutics in Q3 2018 and held it in 4 quarters.
  • Panagora Asset Management's Rein Therapeutics position peaked at $54K in Q1 2019.
  • 22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.